Novo Nordisk and Medical Technologies Education Hub; The time is now: implementing screening of MAFLD in type 2 diabetes management
| Thursday, August 22, 2024 |
| 1:15 PM - 2:00 PM |
| Education Hub - Theatrette 2 |
Details
Join this case-based session where experts discuss recommendations for implementing liver fibrosis assessment when managing type 2 diabetes.
The link between type 2 diabetes (T2D) and the development & progression of metabolic dysfunction-associated fatty liver disease (MAFLD) to metabolic dysfunction-associated steatohepatitis (MASH), is well established. Moreover, T2D is independently associated with an increased risk of adverse hepatic outcomes including decompensated cirrhosis and hepatocellular carcinoma (HCC).
International diabetes guidelines now recommend liver screening using non-invasive tests in all patients with type 2 diabetes as a part of complications assessment.
Join this practical multidisciplinary discussion with Prof Leon Adams (Hepatologist) and Prof Stephen Twigg (Endocrinologist) as they discuss how, when & why to implement liver screening in clinical practice. This interactive session will include practical case scenarios using guideline-recommended non-invasive tests such as fibrosis-4 (FIB-4) and vibration-controlled transient elastography (VCTE).
References: 1. Loomba R, Abraham M, Unalp A, et al. Hepatology 2012; 56: 943-51. 59. 2. Huang DQ, Wilson LA, Behling C, et al. Gastroenterology 2023; 165: 463-472.e5. 3. Huang DQ, Noureddin N, Ajmera V, et al. Lancet Gastroenterol Hepatol 2023; 8: 829-836 4. 4. O'Beirne J, Skoien R, Leggett BA, et al. Med J Aust 2023; 219: 358-365. 5. ADA Diabetes Care. 2024 Jan 1:47(Supl 1):S52-S76 6. EASL-EASD-EASO J Hepatology 2024; Jun 7:1-70.
International diabetes guidelines now recommend liver screening using non-invasive tests in all patients with type 2 diabetes as a part of complications assessment.
Join this practical multidisciplinary discussion with Prof Leon Adams (Hepatologist) and Prof Stephen Twigg (Endocrinologist) as they discuss how, when & why to implement liver screening in clinical practice. This interactive session will include practical case scenarios using guideline-recommended non-invasive tests such as fibrosis-4 (FIB-4) and vibration-controlled transient elastography (VCTE).
References: 1. Loomba R, Abraham M, Unalp A, et al. Hepatology 2012; 56: 943-51. 59. 2. Huang DQ, Wilson LA, Behling C, et al. Gastroenterology 2023; 165: 463-472.e5. 3. Huang DQ, Noureddin N, Ajmera V, et al. Lancet Gastroenterol Hepatol 2023; 8: 829-836 4. 4. O'Beirne J, Skoien R, Leggett BA, et al. Med J Aust 2023; 219: 358-365. 5. ADA Diabetes Care. 2024 Jan 1:47(Supl 1):S52-S76 6. EASL-EASD-EASO J Hepatology 2024; Jun 7:1-70.
Speaker
Professor Leon Adams
MBBS, PhD, FRACP, Hepatologist
University of Western Australia
The time is now: implementing screening of MAFLD in type 2 diabetes management
1:15 PM - 2:00 PMBiography
Leon Adams is a Professor at the Medical School, University of Western Australia and consultant hepatologist in the Liver Transplant Unit at Sir Charles Gairdner Hospital. His research interests focus on translational, clinical and epidemiological aspects of metabolic dysfunction-associated fatty liver disease and non-invasive assessment of liver fibrosis. Leon is co-chair of the GESA MAFLD screening guidelines.
Prof Stephen Twigg
Kellion Professor of Endocrinology, Stan Clark Chair, and Head of Endocrinology Department RPAH
The University of Sydney School of Medicine
: The time is now: implementing screening of MAFLD in type 2 diabetes management
1:15 PM - 2:00 PMBiography
Prof Stephen Twigg is a Clinical Academic, physician-scientist translational researcher, Kellion Professor of Endocrinology and Stan Clark Chair in Diabetes, in the Sydney Medical School, and Charles Perkins Centre, the University of Sydney. Stephen is Chair of the ADS Liver disease special interest group.
